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Background: Several studies show that the regulatory impact of microRNAs (miRNAs) is an essential contribution
to the pathogenesis of colorectal cancer (CRC). The expression levels of diverse miRNAs are associated with specific
clinical diagnoses and prognoses of CRC. However, this association reveals very little actionable information with
regard to how or whether to treat a CRC patient. To address this problem, we use miRNA expression data along
with other molecular information to predict individual response of CRC cell lines and CRC patients.
Methods: A strategy has been developed to join four types of information: molecular, kinetic, genetic and treatment
data for prediction of individual treatment response of CRC.
Results: Information on miRNA regulation, including miRNA target regulation and transcriptional regulation of miRNA,
in integrated into an in silico molecular model for colon cancer. This molecular model is applied to study responses of
seven CRC cell lines from NCI-60 to ten agents targeting signaling pathways. Predictive results of models without and
with implemented miRNA information are compared and advantages are shown for the extended model. Finally, the
extended model was applied to the data of 22 CRC patients to predict response to treatments of sirolimus and
LY294002. The in silico results can also replicate the oncogenic and tumor suppression roles of miRNA on the
therapeutic response as reported in the literature.
Conclusions: In summary, the results reveal that detailed molecular events can be combined with individual
genetic data, including gene/miRNA expression data, to enhance in silico prediction of therapeutic response of
individual CRC tumors. The study demonstrates that miRNA information can be applied as actionable information
regarding individual therapeutic response.
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With an average of 610,000 deaths per year, CRC has
become the second most common cause of cancer death
on a global scale. Because it is most commonly diagnosed
at advanced stages, approximately 50 % of patients diag-
nosed with CRC will surrender to the disease [1]. From a
molecular perspective, CRC is characterized by the accu-
mulation of genetic alterations affecting the cellular func-
tionalities of oncogenes and tumor suppressor genes,
leading to genomic instability and cellular dysfunction [2].
A number of deregulated signaling pathways, most notably
Wnt [3], Notch [4], Hedgehog [5] and others [6, 7], have* Correspondence: lijian@ibe.med.uni-muenchen.de
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growth and cancerous functional integration of CRC. The
signaling network based on these deregulated pathways
steers the oncogenetic development. Furthermore, miR-
NAs are deeply involved in the pathogenesis of CRC by
affecting key components of those signaling pathways.
They play significant roles in regulating cell growth,
proliferation, invasion and metastasis in CRC [8–14].
Moreover, recent studies have demonstrated that
miRNAs detected in blood serum, plasma and even in
stool offer novel non-invasive approaches to diagnose
CRC [13, 15–17]. Other recent studies revealed experi-
mentally that expression levels of certain miRNAs were
associated with specific prognosis and therapeutic
outcomes in CRC, which provides compelling evidence
that miRNAs have the potential to be prognostic and pre-
dictive biomarkers [18–21]. Further, detailed molecularcess article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
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tion was reported in the study of Melo & Kalluri [22]. Our
study introduces an in silico model for the colorectal can-
cer cell which implements miRNA information and




The gene-expression and miRNA-expression data of the
22 CRC patients examined in this study can be down-
loaded from https://tcga-data.nci.nih.gov/tcga/, which is
provided by the Cancer Genome Atlas, with the following
filter setting configuration: Select a disease→COAD- Colon
adenocarchinoma; Data type→ RNASeqV2/miRNASeq;
Center/Platform→All; Batch number→All; Sample→
Patient ID; Data level→ Level 3; Availability→None.
Each dataset was produced through the analysis of
high-quality colon tumor samples from the partici-
pants. Each dataset was normalized using the trimmed
mean of M-values normalization method proposed by
Robinson & Oshlack [23], to remove systematic tech-
nical effects and minimize the sequencing technical
bias on the data.
The Genomic Data of CRC Cancer Cell Lines from NCI-60
The CRC cancer cell lines examined in this study are
COLO-205, HCC-2998, HCT-116, HCT-15, HT29, KM12,
SW-620. The gene-expression data of these cancer cell
lines can be downloaded via [24]. The miRNA-expression
data can be accessed via [25].The Non-Steroidal Anti-Inflammatory Drug (NSAID) Model
Our previous study [26] introduced the in silico NSAID
model, which incorporates information of 20 diverse
CRC-relevant signaling pathways, such as Wnt, Notch,
BMP, beta-catenin and Hedgehog, and other molecular
features. The model contains different types of biological
components such as genes, RNAs, proteins and com-
plexes. Components of the network are used to quantify
specific aspects of tumorigeneity in terms of the cancer
hallmarks [27]. The study demonstrated application for
two therapeutic developmental strategies: synthetic le-
thality and miRNA biomarker discovery.Molecular Addition of miRNA-Regulation (miRAO)
The algorithmic basis for our study is the NSAID model
introduced by Li & Mansmann [26]. The following steps
implement miRNA regulations:
1. Convert miRNA-target data into a data array (miRT)
(with Ensembl-ID as key; miRNA-ID and references(PubMed) as value); for example, miRT
[ENSG00000236342] = (mir-1238, 17964270).
2. Convert the TransmiR data into a data array (TFmiR)
(with miR-ID as key; Ensembl-ID, transcriptional
regulation, references (PubMed) as value); for
example, TFmiR[mir-223] = (ENSG00000159216,
repression, 17996649).
3. Divide the NSAID model (XML file of NSAID) into
different data arrays according to component type
(such as gene array, mRNA array, protein array,
reaction array, etc.)
4. Iterate all the gene components in the gene array;
when a gene with Ensembl-ID matches a key of
miRT, then the corresponding miRNA is created in
the model by defining name, ID, location and other.
Afterwards, the TFmiR is applied to identify the
transcriptional factors that regulate the expression
level of this miRNA. The corresponding type of
transcription reaction is defined to link the miRNA
gene with the miRNA. Afterwards, the miRNA is
translocated into cytoplasm and modeling of its
regulation on the corresponding mRNA is created
and added into the model (Fig. 1). (The detailed
molecular modeling is explained in the study of Li
et al. [28].)Model Initialization with miRNA and Gene Expression Data
The initial value of all components in the model is zero.
The miRNA- and gene-expression data is available
through the link from the Cancer Genome Atlas (as
mentioned in the paragraph “Colorectal Cancer
Patients”) or from the cell line data. These datasets are
converted into a data array (similarly to the method ex-
plained above). The keys of this data array are the
miRNA-IDs and Ensembl-IDs as well as the expression
values. Afterwards, the expression levels of miRNA
genes and normal genes in the model are set to the
values as given by the miRNA-ID and Ensembl-ID.
During Petri net simulation, signal fluxes of reactions
are simulated in the model by transcription reactions
and are expanded to the rest of the model by other
reactions defined in the model. This data initialization
is the input for the Flux Comparative Analysis
explained in the following.Mathematical Implementation of Sirolimus and LY294002
We study the effect of sirolimus as a specific mTor
inhibitor. According to Nashan [29], its dissociation con-
stant is 0.65 nM indicating an inhibition of biochemical
reactions catalyzed by the mTor protein complex.
LY294002 is a potent inhibitor of PI3K, which catalyzes
the conversion from PIP2 to PIP3. The dissociation con-
stant of LY294002 is 210 nM [30]. Table 1 contains the
Fig. 1 The conceptual visualization of miR-add-on algorithm. The step (1) simplifies two biological processes: (a) the transcription catalyzed by
transcriptional activator or repressor (if available); (b) the primary transcript (pri-miRNA) is cropped into a hairpin intermediate (pre-miRNA) by the
nuclear 650 kDa microprocess complex, which consists of humans of the RNase III DROSHA (RNASEN) and the DiGeorge syndrome critical region
gene 8 (DGCR8) . The step (2) defines a transport reaction to translocate the miRNA into cytoplasm so that it is ready for the following target
binding process. The step (3) is a degradation process. The step (4) simplifies two processes: (a) mature miRNA binds to different protein partners
and turns into the RNA-induced silencing complex (RISC); (b) RISC recognizes the target mRNA and binds to it. The steps (5), (6) and (7) are
transcription, translation and degradation of target gene, mRNA and protein, respectively
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ing control state (without treatment).
Flux Comparative Analysis (FCA)
The FCA is an advanced Petri net simulation strategy.
As the name suggests, it is an analysis of flux comparisonof two different states of a molecular model. The goal of
FCA analysis is to detect whether a therapeutic interven-
tion (drug treatment) can cause a significant flux change
with regard to the structure of an entire molecular net-
work, in order to predict how an individual would
respond to a therapeutic intervention [26]. Essentially,
Table 1 'E': enzyme; 'I': Inhibitor. Currently, we have only applied the mass action law for implementing biochemical reaction
Sirolimus treatment CRC patient + sirolimus CRC patient
Molecular modeling mTor complex II (E); Sirolimus (I) mTor complex II (E)
PRKCG + ATP→→→ P-PRKCG + ADP PRKCG + ATP→→→ P-PRKCG + ADP
mTor complex II (E); Sirolimus (I) mTor complex II (E)
SGK + ATP→→→ P-SGK + ADP SGK + ATP→→→ P-SGK + ADP
mTor complex II (E); Sirolimus (I) mTor complex II (E)
PRKCA + ATP→→→ P-PRKCA + ADP PRKCA + ATP→→→ P-PRKCA + ADP
mTor complex II (E); Sirolimus (I) mTor complex II (E)
AKT + ATP→→→ P-AKT + ADP AKT + ATP→→→ P-AKT + ADP
mTor complex II (E); Sirolimus (I) mTor complex II (E)
HIF1A + ATP→→→ P-HIF1A + ADP HIF1A + ATP→→→ P-HIF1A + ADP
mTor complex II (E); Sirolimus (I) mTor complex II (E)
PPARGC1 + ATP→→P-PPARGC1 + ADP PPARGC1 + ATP→ P-PPARGC1 + ADP
mTor complex II (E); Sirolimus (I) mTor complex II (E)
EIF4EBP + ATP→→ P-EIF4EBP + ADP EIF4EBP + ATP→→P-EIF4EBP + ADP
mTor complex II (E); Sirolimus (I) mTor complex II (E)
PPARG + ATP→→ P-PPARG + ADP PPARG + ATP→→ P-PPARG + ADP
LY294002 treatment CRC patient + LY294002 CRC patient
Molecular modeling Enzymes; LY294002 (I) Enzymes
PIP2 + ATP→→→ PIP3 + ADP PIP2 + ATP→→→ PIP3 + ADP
For instance, the substance A and B participate in a reaction catalyzed by an enzyme and inhibitor to produce the products C and D: enzyme; inhibitor
A + B→→→ C + D
where the mathematical implementation: [C] = [D] = [A] * [B] * [enzyme] * [iKd] / [inhibitor] * [eKd], eKd: enzymatic dissociation constant; iKd: inhibitor
dissociation constant
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patient for each treatment: one is the control state
(without treatment) and the other is the perturbation
state (with treatment). During the Petri net simulation,
the fluxes generated for each state in the model are
compared for each patient. The following simulation
algorithm code is applied to generate the steady state of
each state:
Ri = the i-th reaction in the molecular model; Parameters
of Ri include speed (S), kinetic parameter (k), product
(p), reactant (a), enzyme (e)
Cj,t = the concentration of the j-th bio-object (such as
gene, protein) in the model at time step t
St = Ca,t * Ce,t * k
N, M = the number of reactions and bio-objects in the
model, respectively.
1. Input: Gene-expression data and miRNA-expression
data
2. For each j (from 1 to M) at time step t:
3. if Cj,t – Cj,t-5 > 0.001:
4. then reachSteadyState = False
5. If not reachSteadyState:
6. for each i (from 1 to N) at time step t:7. if Cp,t-1 < Ca,t-1 & St < Ca,t-1 * 0.75:
8. then evaluate Ri as Petri net firing rule at t:
9. Cp,t = Cp,t-1 + St
10. Ca,t = Ca,t-1 - St
11. If reachSteadyState:
12. select the readout components
13. Output: compare readout components between two
states (Control vs. Treatment)Definition of Sensitivity Score for Drug Response
Experimentally based sensitivity score (experimental
data) = GI50
(GI50: the -log mol/L drug/concentration yielding a
growth inhibition of 50 %, [31])
Model-based sensitivity score (prediction data) =
log(P) + K
(P: relative change value of readout component
'proliferation' hallmark in the treatment state com-
pared to that in the control state. In this case, the
hallmark 'proliferation' is selected as the readout
component for the FCA analysis; K: constant value,
currently estimated as 5.2. the hallmark "prolifera-
tion", as a mirror of proliferative ability, is taken as
the primary outcome, since the cell line models
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lular growth)
Correlation Between Experimentally Measured and
Computationally Simulated Scores
It is of interest to calculate the Pearson correlation
between observed and predicted response of cell lines
under a specific treatment. Aggregating correlation over
all treatments was calculated following the principles of
Bland and Altman as presented in [32].
The Availability of the Model
The XML file of the NSAID-miR model is available
under [33].
Results
A strategy for prediction of individual treatment response
is proposed which is based on an in silico environment in
which the molecular regulation effect of miRNAs com-
bined with other molecular information can be utilized. A
flowchart depicts the work-flow of this concept (Fig. 2).
There are four major sources of input information: mo-
lecular, kinetic, individual genetic (miRNA/mRNA ex-
pression data) and treatment data.
The microRNA Extension for the Non-Steroidal
Anti-Inflammatory Drug (NSAID) Model
The NSAID model depicts a consolidated molecular basis
of CRC which is extended in this study by including
miRNA regulation. An algorithm, the miRNA-add-on
(miRAO), is proposed which automatically adds miRNA
regulation into molecular models such as the NSAID
model. The miRAO checks whether each miRNA hasFig. 2 The work-flow of the molecular concept for individualized medicine. In
treatment, four types of information are currently needed as input to constru
achieve the goal of individualized medicinebeen validated with targets according to a specified
miRNA-target database (Additional file 1) and whether
each miRNA has validated transcription factors (TFs)
according to the TransmiR database (version 1.2), which
provides detailed information regarding type and effect
of transcriptional regulations on miRNAs with corre-
sponding literature [34]. If such validated gene targets
or miRNA transcription factors are available, then the
miRAO adds the molecular miRNA regulation to the
model (Fig. Methods;). In this way, the NSAID model is
extended with available validated miRNA-target and
TF-miRNA information, which strengthens the model
with detailed molecular regulation mechanisms related
to miRNA. The new version of the model is named
NSAID-miR; a summarization is given in Table 2.Therapeutic Prediction of Ten Signaling Agents on CRC
Cancer Cell Lines
In order to validate the NSAID-miR model, the inhib-
ition effects of ten signaling agents on seven CRC
cancer cell lines are simulated and compared to experi-
mentally measured inhibition effects (sensitivity scores)
from the study of Holbeck et al. [31]: COLO-205,
HCC-2998, HCT-116, HCT-15, HT29, KM-12, and
SW-620. The NSAID-miR model is initialized with
gene-expression and miRNA-expression data of indi-
vidual CRC cancer cell lines (Methods). The effects of
ten signaling agents are studied: dasatinib, erlotinib,
everolimus, gefitinib, imatinib, lapatinib, nilotinib, so-
rafenib, sunitinib, and temsirolimus. The inhibition
potential of these tyrosine-kinase inhibitors can be spe-
cified through corresponding dissociation constants.
They were measured experimentally by Karaman andorder to reflect or capture the individual patient response to specific
ct a molecularly based model, which might act as a 'Virtual Patient' to
Table 2 The component/reaction summary of the
NSAID-miR model
Component No. Reaction No.
Gene 1284 Transcription 1933
mRNA 2360 Translation 898
Protein 1473 Decay 2172
miRNA 367 Complex-formation 579
Compound 44 Translocation 1361
Complex 856 Phosphorylation 749
Pseudo-object 21 Dephosphorylation 357
SiRNA 1 Activation 341
miRNA-binding 1516
Sum: 6406 Sum: 9906
Table 3 Ten signaling agents and their targets with dissociation
constant



































The experimentally measured dissociation constants of these signaling agents
were mainly taken from Karaman et al. [35]
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eled is described in Table 3. Subsequently, we per-
formed the FCA to calculate the simulated sensitivity
scores of the cell lines (Methods) and supplies kinetic
data. The Pearson correlation is used to compare the
model-based sensitivity scores to the experimentally
based sensitivity scores measured under the in vitro
condition by Holbeck et al. [31]. Among these sig-
naling agents, the dasatinib (0.964, p = 2.78e-03),
everolimus (0.929, p = 6.75e-03), imatinib (0.893, p =
1.23e-02), and sunitinib (0.821, p = 3.41e-02) have
high correlations of sensitivity scores (>0.80, Fig. 3a-c,
Additional file 2). We also quantified the correlation
between everolimus and temsirolimus treatment re-
sponse of CRC cell lines measured by GI-50 and the
model-based sensitivity score using the R2 measure.
Under everolimus, R2 = 0.9713, and under temsiroli-
mus, R2 = 0.9824. (Fig. 3d). These high correlations pro-
vide evidence that the NSAID-miR model captures
drug effects in the CRC cellular system.
Lapatinib (0.679, p = 1.10e-02) has the lowest correl-
ation of sensitivity scores (Fig. 3b, Additional file 2). The
reason for this relatively low prediction rate could be
that the inhibition effect of lapatinib in the NSAID-miR
is only determined by the inhibition of three members of
the ERBB-family. The dissociation constant between
lapatinib and ERBB4 is relatively high (54 nM), which
further weakens the effect of lapatinib in the NSAID-
miR (Table 3). The overall correlation of the sensitivity
scores of all ten drug treatments is 0.947. However,
without use of miRNA expression data as input data for
the in silico model, the same approach only achieved an
overall correlation of 0.838 (Fig. 4). This difference (p-
value: 0.021) indicates the value of miRNA expression
profiles in better understanding the molecular mecha-
nisms of cellular systems and their essential role in the
prediction of therapeutic responses.Therapeutic Prediction of CRC Patients with Microsatellite
Instability (MSI) and Microsatellite Stability (MSS)
Microsatellites are short repetitive DNA sequences that
are prone to frameshift mutations and base-pair sub-
stitutions during duplication. MSI is one of the most
extensively investigated genetic phenotypes, and is de-
tected in approximately 15 % of CRC cases [36]. Many
studies provide evidence that CRC with MSI status is
associated with favorable clinical outcomes [37–41].
Fig. 3 Sensitivity scores of CRC cancer cell lines. a: the plot visualizes how CRC cancer cell lines respond to the treatment of dasatinib, erlotinib, and
everolimus. b: the plot quantitatively displays how CRC cancer cell lines respond to the treatment of gefitinib, imatinib and lapatinib. c: the plot
quantitatively shows how CRC cancer cell lines respond to the treatment of nilotinib, sorafenib, sunitinib and temsirolimus. All data are attached in the
Additional file 2 (Exp: experimentally based sensitivity score; Sim: model-based sensitivity score). d: R2 measure between responses (GI-50) of CRC cell
lines and predicted sensitivity scores to treatments of everolimus and temsirolimus
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lated to the predictive value of MSI [42–45]; clearly,
there is uncertainty as to the predictive ability of this
genetic phenotype in clinical practice. In response to
this, we apply the NSAID-miR model to predict the
therapeutic responses of MSI/MSS patients. Moreover,
we investigate the molecular mechanisms leading to
the discrepancy between the clinical outcomes of indi-
vidual colon cancer patients with MSI status versusthose with MSS status. From the Cancer Genome Atlas
[46], we obtained genetic data, including miRNA/gene-ex-
pression data and patient information (age, sex, race, can-
cer stage and other) of 22 colon cancer patients
(Additional file 3), of which eleven have MSS status, and
eleven MSI; the patients' cancer stages range from I to III.
Further, two recent studies demonstrated that both drugs
sirolimus and LY294002 (targeting mTor- and PI3K-
signaling pathways, respectively) clearly reduced the
Fig. 4 Single points represent reaction of a specific cell line under a specific treatment. Different colours represent different treatments. Overall
correlation: without miRNA information 0.838, with miRNA information 0.947, p-value for difference in correlation structure given miRNA information
(yes, no) p = 0.021
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order to investigate this issue with the application of the
NSAID-miR model, we initialized the model with the
gene-expression and miRNA-expression data of these pa-
tients individually (Methods). Subsequently, we performed
the FCA to predict how these individual patients would
respond to drug treatments.
The results show that all MSS patients would not re-
spond to the sirolimus treatment, regardless of colon
cancer stage (Fig. 5). Among the eleven MSI patients, we
found that two patients with advanced cancer stage III
would not respond to the sirolimus treatment, while the
remaining nine MSI patients would. In general, the pre-
dictions are in agreement with the results from the
aforementioned studies [47, 48]. Further, our results
support the finding that the prognosis for MSI tumors
in stage III CRC is poor [49]. Taking model based
miRNA level as readouts of model NSAID-miRNA, FCA
results between MSI and MSS patients after treatment
show that the expression levels of miR-18a, −19a, −203,
−224, and −92 are downregulated on average by >15 %
(p = 3.49e-06) in patients with stages I and II. The expres-
sion levels of miR-181b, −183, −20a, −21, −31 and −96 are
downregulated on average by >15 % (p = 6.09e-04) in pa-
tients with stage III (Fig. 6a; Additional file 4). The
expression levels of miR-30a, −143, −145, −200b and −378
are upregulated on average by >1.8 fold (p = 7.84e-06) in
patients of all stages (Additional file 4).Two male African Americans in cancer stages IIA
and IIIC among eleven MSS patients would respond
to the LY294002 treatment. Further investigation of
the FCA result shows that the expression levels of
mir-21, −140, −188, −216, −224, −374, −503 and −675
were reduced in these two patients after treatment
(Fig. 6b; Additional file 4). Eight among eleven MSI
patients would respond to the LY294002 treatment.
Interestingly, we found that the three MSI patients
with CRC stage III, who would not respond to the
LY294002 treatment, showed high activity of the cell-
cycle pathway, and the expression levels of mir-21,
−34a, −95, −135a and −320 remained nearly un-
changed after this treatment (Additional file 4). This
result might reveal the key miRNA-regulators that
negatively contribute to the clinical outcome of MSI
patients. Furthermore, by using a ROC curve and the
corresponding AUC, we quantified the discrimination
between response between MSS and MSI patients
through the in silico prediction given by our model.
The AUC for response prediction under sirolimus is
0.876, The AUC for response prediction under LY294002
is 0.715. (Fig. 7)
Conclusion & Discussion
This study introduces a concept which integrates differ-
ent types of molecular data for individualized medicine.
It uses an in silico environment to capture the molecular
Fig. 5 Simulated response of drug treatments. The model component 'proliferation' is considered as the readout component of this FCA analysis,
which compares the flux from treatment state with the flux from control state of each patient. Patients with hallmark proliferation smaller than 1
are considered responders, while those with hallmark proliferation bigger than 1 are considered non-responders
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cellular systems (Fig. 2). Four major sources of input
information are used to calculate the individual response
of the system: molecular, kinetic, individual genetic
(miRNA/mRNA expression data) and treatment data.
The internal network structure of the NSAID-miR
model covers molecular signaling pathways (including
transcription and translation, protein-protein interaction,
and protein modification) and miRNA regulation. The
kinetic data describes kinetic values of different types of
reactions (such as transcription, phosphorylation, complex
formation, receptor-ligand-binding) and allows to imple-
ment the treatment effects. The kinetic data impacts the
signal flow (defining classical chemical reactions of sub-
strates for producing products with or without modifiers)
throughout the network. Contrasting the flux in the un-
treated cell with the flux of the treated cell allowsquantifying changes in the cancer hallmarks. These
changes can be used to predict treatment response of the
system.
During this study, data of CRC cell lines as well as
patients were used for the validation. For ten agents,
we simulated the responses of seven CRC cell lines and
compared them to their in vitro drug response data.
There is high correlation, which indicates the reliability
and precision of the predictions of the proposed model.
In order to give a first demonstration of the potential
clinical usefulness of this concept, we received the
miRNA and gene expression data of 22 MSI/MSS pa-
tients provided by the Cancer Genome Atlas [46] for
predicting the clinical outcome of the sirolimus and
LY294002 treatments. The prediction results show that
most MSI patients would respond to both drug treat-
ments, however most MSS patients would not. At the
Fig. 6 Simulated miRNA expression pattern after treatments. The simulated result reveals that global miRNA expression profile can be changed due to
the drug treatment. According to the expression patterns, both treatments have more significant impact on the MSI patients than MSS patients.
However, specific patients may have individual treatment responses
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Fig. 7 ROC analysis of discrimination of treatment responses between MSS and MSI patients
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is still not available. But our result is in accordance
with clinical knowledge that MSI status is related to
the response of the treatment under study [47,48].
Based on our results, we strongly hypothesize that
one molecular reason for better therapeutic outcomes
of MSI patients could be the upregulation of tumor-
suppressor miRs and downregulation of oncogenic
miRs, which drives the cellular system of patients
with MSI status away from the full-fledged malignant
cellular state with strong drug resistance and uncon-
trolled proliferation.
In a recent study, Ellwanger and colleagues [50] de-
cipher the role of miRNA on a large scale, which provides
knowledge for the implementation of miRNA regulation
in molecular in silico models. We see that many of their
findings are already implemented in our NSAID-miR
model, for instance, the regulation mechanisms of mir-
21, mir-181 and let-7. However, the NSAID-miR model
might be the first molecular signaling model which
contains not only validated miRNA-target relationship
information but also includes literature-referenced rela-
tionships between transcription factors and miRNAs. In
addition, the NSAID-miR model can be applied to in-
vestigate therapeutic response of patients with cancers
beyond CRC. For instance, we are studying a genome-
scale model of acute myeloid leukemia (AML) to predict
individual response to AML clinical treatments; the results
achieved thus far are promising (data not shown), which
indicates that our approach also possesses the potential to
be extended to diverse other cancer types. However, one
limitation of our model is the applied kinetic data, which
is mainly determined through empirical experience. How
to perform appropriate estimates in patient groups
(depending on age, sex, etc.) is the issue of our future
research. Furthermore, our concept does not consider
metabolic molecular information. This is another chal-
lenge of future research.Additional file
Additional file 1: Validated miRNA target with literature reference.
Additional file 2: Experimentally based sensitivity score and model-
based sensitivity score for treatments of ten signaling agents with
and without consideration of miRNA expression data.
Additional file 3: Patient Information.
Additional file 4: Comparison result between treatment state and
control state from the FCA analysis.
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